2020 / 03

Next Paper
DOI: 10.24075/brsmu.2020.027

ORIGINAL RESEARCH

Aspects of free radical oxidation in the large bowel in ulcerative colitis and Crohn’s disease

Osikov MV1, Davydova EV1, Boyko MS1, Bakeeva AE1, Kaygorodtseva NV1, Galeeva IR1, Fedosov AA2, Ilyinyh MA1, Vorgova LV1
About authors

1 South Ural State Medical University, Chelyabinsk

2 Pirogov Russian National Research Medical University, Moscow, Russia

Correspondence should be addressed: Mikhail V. Osikov
Vorovskogo, 64, Chelyabinsk, 454092; ur.xednay@vokiso.forp

About paper

Compliance with ethical standards: the study was approved by the Ethics Committee of South Ural State Medical University, Chelyabinsk (Protocol No. 11 dated December 27, 2017; Protocol № 1 dated January 22, 2020). The experiment was carried out under standard vivarium conditions in strict compliance with the guidelines on the care and use of animals for scientific purposes provided in the European Convention (ETS № 123 dated March 18, 1986, Strasbourg), European Commission Recommendation 2007/526/EC dated June 18, 2007, and Directive 2010/63/EU of the European Parliament and European Council dated September 22, 2010.

Author contribution: Osikov MV conceived and designed the study, analyzed the experimental data and contributed to writing the manuscript; Davydova EV conceived and designed the study, analyzed the experimental data and contributed to writing the manuscript; Boyko MS, Bakeeva AE, Kaygorodtseva NV, Galeeva IR collected the samples, performed statistical analysis and data interpretation; Fedosov AA analyzed the experimental data and contributed to writing the manuscript; Ilyinyh MA, Vorgova LV analyzed the experimental data and contributed to writing the manuscript. All authors read and approved the final version of the manuscript for publication.

Received: 2020-04-18 Accepted: 2020-05-04 Published online: 2020-05-08
|
  1. Corridoni D, Arseneau KO, Cominelli F. Inflammatory bowel disease. Immunology Letters. 2014; 161 (2): 231–35.
  2. Dolgushina AI, Husainova GM, Vasilenko GM, Kononenko AG. Rasprostranennost' vospalitel'nyh zabolevanij kishechnika v Chelyabinskoj oblasti. Al'manah klinicheskoj mediciny. 2019; 47 (6): 511–17. Russian.
  3. Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015; 50 (8): 942–51.
  4. Su HJ, Chiu YT, Chiu CT, Lin YC, Wang CY, Hsieh JY, et al. Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates. J Formos Med Assoc. 2019; 118 (7): 1083–92.
  5. Gajendran M, Loganathan P, Catinella AP, Hashash JG A comprehensive review and update on Crohn's disease. Dis Mon. 2018 Feb; 64 (2): 20–57.
  6. Ray G, Longworth MS. Epigenetics, DNA Organization, and Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019; 25 (2): 235–47.
  7. Lee SH, Kwon JE, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018; 16 (1): 26–42.
  8. Tian T, Wang Z, Zhang J. Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies. Oxid Med Cell Longev. 2017; 2017: 4535194.
  9. Zhen Y, Zhang H. NLRP3 Inflammasome and Inflammatory Bowel Disease. Front Immunol. 2019; 10 (276). URL: https://www. frontiersin.org/articles/10.3389/fimmu.2019.00276/full (дата обращения: 24.04.2020).
  10. Kiernan MG, Coffey JC, Sahebally SM, Tibbitts P, Lyons EM, O’Leary E, et al. Systemic molecular mediators of inflammation differentiate between Crohn's disease and ulcerative colitis, implicating threshold levels of IL10 and relative ratios of pro-inflammatory cytokines in therapy. J Crohns Colitis. 2020; 14 (1): 118–119.
  11. Assadsangabi A, Evans CA, Corfe BM, Lobo A. Application of Proteomics to Inflammatory Bowel Disease Research: Current Status and Future Perspectives. Gastroenterol Res Pract. 2019; 2019: 1426954.
  12. Titz B, Gadaleta RM, Lo Sasso G, Elamin A, Ekroos K, Ivanov NV, et al. Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification. Int J Mol Sci. 2018; 19 (9): 2775–96.
  13. Ashton JJ, Mossotto E, Ennis S. Personalising medicine in inflammatory bowel disease-current and future perspectives. Transl Pediatr. 2019; 8 (1): 56–69.
  14. Morris GP, Beck PL, Herridge MS, et. al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989; 3: 795–803.
  15. Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W. Oxazolone Colitis, a Th2 Colitis Model Resembling Ulcerative Colitis Is Mediated by IL13-Producing NK-T Cells. Immunity. 2002; 17 (5): 629–38.
  16. Cooper HS, Murthy SN, Shah RS, et. al. Clinicopathologic study of dextran sulfate sodium ex- perimental murine colitis. Lab Invest. 1993; 69 (2): 238–49.
  17. Kim JJ, Shajib MS, Manocha MM, Khan WI. Investigating intestinal inflammation in DSS-induced model of IBD. Journal of visualised experiments. 2012; 60 (60): 3678.
  18. Volchegorskij IA, Dolgushin II, Kolesnikov OL, Cejlikman VJe. Jeksperimental'noe modelirovanie i laboratornaja ocenka adaptivnyh reakcij organizma. Cheljabinsk: ChelGPU, 2000; 167 s. Russian.
  19. Lvovskaya, EI, Volchegorskij IA, Shemyakov SE, Lifshic RI. Spektrofotometricheskoe opredelenie konechnyh produktov POL. Voprosy med. himii. 1991; 4: 92–93. Russian.
  20. Dubinina EE. Produkty metabolizma kisloroda v funkcional'noj aktivnosti kletok (zhizn' i smert', sozidanie i razrushenie). Fiziologicheskie i kliniko-biohimicheskie aspekty. SPb.: Medicinskaya pressa, 2006; 400 s. Russian.
  21. Fomina MA. Sposob kompleksnoj ocenki soderzhaniya produktov okislitel'noj modifikacii belkov v tkanyah i biologicheskih zhidkostyah: metodicheskie rekomendacii. Ryazan', 2014; 60 s. Russian.
  22. Antoniou E, Margonis GA, Angelou A, Pikouli A, Argiri P, Karavokyros I, et al. The TNBS-induced colitis animal model: An overview. Ann Med Surg (Lond). 2016; 11: 9–15.
  23. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007; 2 (3): 541–6.
  24. Bramhall M, Flórez-Vargas O, Stevens R, Brass A, Cruickshank S. Quality of methods reporting in animal models of colitis. Inflamm Bowel Dis. 2015; 21 (6): 1248–59.
  25. Randhawa PK, Singh K, Singh N, Jaggi AS. A review on chemical-induced inflammatory bowel disease models in rodents. Korean J Physiol Pharmacol. 2014; 18 (4): 279–88.
  26. Weigmann B, Neurath MF. Oxazolone-induced colitis as a model of Th2 immune responses in the intestinal mucosa. Methods Mol Biol. 2016; 1422: 253–61.
  27. Ikeda M, Takeshima F, Isomoto H, Shikuwa S, Mizuta Y, Ozono Y, et al. Simvastatin attenuates trinitrobenzene sulfonic acid-induced colitis, but not oxazalone-induced colitis. Dig Dis Sci. 2008; 53: 1869–75.
  28. 28. Gubskij YuI, Belenichev IF, Levinskij EL, Kovalenko SI, Pavlov SV, Gancheva OV, i dr. Toksikologicheskie posledstviya okislitel'noĭ modifikacii belkov pri razlichnyh patologicheskih sostoyaniyah. Sovremennye problemy toksikologii. 2005; 8 (3): 20–27.
  29. Dalle-Donne I, Scaloni A, Giustarini D, Cavarra E, Tell G, Lungarella G, et al. Proteins as biomarkers of oxidative stress in diseases: the contribution of redox proteomics. Mass Spectrom Rev. 2005; 24: 55–99.
  30. Muravleva LE, Molotov-Luchanskij VB, Klyuev DA, Bakenova RA, Kultanov BZH, Tankibaeva NA, i dr. Okislitel'naya modifikaciya belkov: problemy i perspektivy issledovaniya. Fundamental'nye issledovaniya. 2010; 1: 74–78. Russian